Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a significant decline in short interest in August. As of August 14th, there was short interest totaling 190,290 shares, a decline of 39.0% from the July 30th total of 311,827 shares. Based on an average daily volume of 1,508,069 shares, the short-interest ratio is presently 0.1 days. Approximately 1.5% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Thursday, August 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Capstone Therapeutics Stock Performance

Shares of NASDAQ:CAPS remained flat at $0.18 during midday trading on Tuesday. 130,482 shares of the stock were exchanged, compared to its average volume of 1,784,630. The business has a 50 day moving average price of $0.24 and a 200 day moving average price of $0.40. Capstone Therapeutics has a one year low of $0.17 and a one year high of $1.57. The stock has a market cap of $3.81 million, a price-to-earnings ratio of -0.06 and a beta of -1.52. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.39.

Institutional Trading of Capstone Therapeutics

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC acquired a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.55% of the company’s stock.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.